The global oral solid dosage contract manufacturing market size is expected to reach $54.7B by 2030, registering a CAGR of 6.0% over the forecast period, according to a new report by Grand View Research, Inc. Increasing complexity of new drug molecules, R&D investments by large Contract Manufacturing Organizations (CMOs) & Contract Development & Manufacturing Organization (CDMOs), and rising demand for new therapies would drive the growth of the market. Oral solids are the most widely accepted dosage forms in the pharmaceutical sector as they are cost-effective, simple to manufacture, and patient-friendly. Furthermore, advances in drug delivery technology, such as the delivery of drugs and sustained release formation, are enabling oral solids to achieve even higher levels of bioavailability while lowering drug administration frequency.
-
The tablets segment dominated the market in 2021. Tablets are the most common OSD forms. It is the most popular dosage due to its compactness, easy manufacturing, and convenience of self-administration.
-
Increased demand for bilayer tablets and investments by firms to expand formulation and controlled-release tablet manufacturing drive the market growth.
-
Based on end-user, the large-size companies segment accounted for the largest revenue share in 2021. The solid dose manufacturing market is increasingly defined by collaboration, flexibility, and a high level of adaptability.
-
As more pharma developers design drugs from the start with the intention of outsourcing them to large CMOs, it's only natural that large CMOs gain more leverage in the development pipeline.
-
Asia Pacific led the global market in 2021 and is projected to witness the fastest CAGR during the forecast years as China and India are the powerhouses of OSD CMO with significantly lower prices.